<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240207211355&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240207211355&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0)</generator>
<language>en</language>
<lastbuilddate>Thu, 08 Feb 2024 02:13:56 +0000</lastbuilddate>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Beyond traditional cardiovascular risk factors: exploring the hidden side of the moon</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38324716/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240207211355&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 7;45(6):407-410. doi: 10.1093/eurheartj/ehae055.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38324716/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240207211355&v=2.18.0">38324716</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae055>10.1093/eurheartj/ehae055</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38324716</guid>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-02-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Beyond traditional cardiovascular risk factors: exploring the hidden side of the moon</dc:title>
<dc:identifier>pmid:38324716</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae055</dc:identifier>
</item>
<item>
<title>β-Blocker Withdrawal and Functional Capacity Improvement in Patients With Heart Failure With Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38324280/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240207211355&amp;v=2.18.0
      <description>CONCLUSIONS AND RELEVANCE: In this study, results showed that in patients with HFpEF and chronotropic incompetence receiving treatment with β-blocker, lower iLVESV may identify those with a greater short-term improvement in maximal functional capacity after stopping β-blocker treatment. Further studies are warranted for further investigation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Feb 7. doi: 10.1001/jamacardio.2023.5500. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Increasing the patient's heart rate (HR) has emerged as a therapeutic option in patients with heart failure with preserved ejection fraction (HFpEF). However, the evidence is conflicting, and the profile of patients who benefit most from this strategy remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess the association of β-blocker treatment withdrawal with changes in the percentage of predicted peak oxygen consumption (VO2) across indexed left ventricular diastolic (iLVEDV) and indexed left ventricular systolic volumes (iLVESV), and left ventricular ejection fraction (LVEF) in patients with HFpEF and chronotropic incompetence.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis was conducted using data from the investigator-blinded multicenter, randomized, and crossover clinical trial, PRESERVE-HR, that took place from October 1, 2018, through December 31, 2020, to investigate the short-term effects (2 weeks) of β-blocker withdrawal on peak oxygen consumption (peak VO2). Patients with stable HFpEF (New York Heart Association functional class II to III) receiving treatment with β-blocker and chronotropic incompetence were included.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Participants in the PRESERVE-HR trial were randomized to withdraw vs continue with β-blocker treatment. After 2 weeks, they were crossed over to receive the opposite intervention. This crossover randomized clinical trial examined the short-term effect of β-blocker withdrawal on peak VO2.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was to evaluate the association between β-blocker withdrawal and short-term changes in percentage of peak VO2 across iLVEDV, iLVESV, and LVEF in patients with HFpEF and chronotropic incompetence treated with β-blocker.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 52 patients (mean age, 73 [SD, 13] years; 60% female) were randomized. The mean resting HR, peak HR, peak VO2, and percentage of peak VO2 were 65 (SD, 9) beats per minute (bpm), 97 (SD, 15) bpm, 12.4 (SD, 2.9) mL/kg per minute, and 72.4% (SD, 17.7%), respectively. The medians (minimum-maximum) of iLVEDV, iLVESV, and LVEF were 44 mL/m2 (IQR, 19-82), 15 mL/m2 (IQR, 7-32), and 64% (IQR, 52%-78%), respectively. After stopping β-blocker treatment, the median increase in peak HR was plus 30 bpm (95% CI, 25-35; P &lt; .001). β-Blocker cessation was differentially associated with change of percentage of peak VO2 across the continuum of iLVESV (P for interaction = .02), indicating a greater benefit in those with lower iLVESV.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this study, results showed that in patients with HFpEF and chronotropic incompetence receiving treatment with β-blocker, lower iLVESV may identify those with a greater short-term improvement in maximal functional capacity after stopping β-blocker treatment. Further studies are warranted for further investigation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov (NCT03871803).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38324280/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240207211355&v=2.18.0">38324280</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5500>10.1001/jamacardio.2023.5500</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38324280</guid>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Patricia Palau</dc:creator>
<dc:creator>Rafael de la Espriella</dc:creator>
<dc:creator>Julia Seller</dc:creator>
<dc:creator>Enrique Santas</dc:creator>
<dc:creator>Eloy Domínguez</dc:creator>
<dc:creator>Vicent Bodí</dc:creator>
<dc:creator>Juan Sanchis</dc:creator>
<dc:creator>Eduardo Núñez</dc:creator>
<dc:creator>Antoni Bayés-Genís</dc:creator>
<dc:creator>Vicente Bertomeu-González</dc:creator>
<dc:creator>Markus Meyer</dc:creator>
<dc:creator>Julio Núñez</dc:creator>
<dc:date>2024-02-07</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>β-Blocker Withdrawal and Functional Capacity Improvement in Patients With Heart Failure With Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:38324280</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5500</dc:identifier>
</item>
<item>
<title>Transient Monocular Blindness in a Man in His 30s</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38324274/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240207211355&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Feb 7. doi: 10.1001/jamacardio.2023.5508. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38324274/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240207211355&v=2.18.0">38324274</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5508>10.1001/jamacardio.2023.5508</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38324274</guid>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Jérôme Antonelli</dc:creator>
<dc:creator>Jean-Philippe Verhoye</dc:creator>
<dc:creator>Raphaël P Martins</dc:creator>
<dc:date>2024-02-07</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Transient Monocular Blindness in a Man in His 30s</dc:title>
<dc:identifier>pmid:38324274</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5508</dc:identifier>
</item>
<item>
<title>Ischaemic heart disease in patients with cancer</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38323638/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240207211355&amp;v=2.18.0
      <description>Cardiologists are encountering a growing number of cancer patients with ischaemic heart disease (IHD). Several factors account for the interrelationship between these two conditions, in addition to improving survival rates in the cancer population. Established cardiovascular (CV) risk factors, such as hypercholesterolaemia and obesity, predispose to both IHD and cancer, through specific mechanisms and via low-grade, systemic inflammation. This latter is also fuelled by clonal haematopoiesis of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 7:ehae047. doi: 10.1093/eurheartj/ehae047. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiologists are encountering a growing number of cancer patients with ischaemic heart disease (IHD). Several factors account for the interrelationship between these two conditions, in addition to improving survival rates in the cancer population. Established cardiovascular (CV) risk factors, such as hypercholesterolaemia and obesity, predispose to both IHD and cancer, through specific mechanisms and via low-grade, systemic inflammation. This latter is also fuelled by clonal haematopoiesis of indeterminate potential. Furthermore, experimental work indicates that IHD and cancer can promote one another, and the CV or metabolic toxicity of anticancer therapies can lead to IHD. The connections between IHD and cancer are reinforced by social determinants of health, non-medical factors that modify health outcomes and comprise individual and societal domains, including economic stability, educational and healthcare access and quality, neighbourhood and built environment, and social and community context. Management of IHD in cancer patients is often challenging, due to atypical presentation, increased bleeding and ischaemic risk, and worse outcomes as compared to patients without cancer. The decision to proceed with coronary revascularization and the choice of antithrombotic therapy can be difficult, particularly in patients with chronic coronary syndromes, necessitating multidisciplinary discussion that considers both general guidelines and specific features on a case by case basis. Randomized controlled trial evidence in cancer patients is very limited and there is urgent need for more data to inform clinical practice. Therefore, coexistence of IHD and cancer raises important scientific and practical questions that call for collaborative efforts from the cardio-oncology, cardiology, and oncology communities.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38323638/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240207211355&v=2.18.0">38323638</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae047>10.1093/eurheartj/ehae047</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38323638</guid>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Pietro Ameri</dc:creator>
<dc:creator>Edoardo Bertero</dc:creator>
<dc:creator>Marco Lombardi</dc:creator>
<dc:creator>Italo Porto</dc:creator>
<dc:creator>Marco Canepa</dc:creator>
<dc:creator>Anju Nohria</dc:creator>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Alexander R Lyon</dc:creator>
<dc:creator>Teresa López-Fernández</dc:creator>
<dc:date>2024-02-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Ischaemic heart disease in patients with cancer</dc:title>
<dc:identifier>pmid:38323638</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae047</dc:identifier>
</item>
<item>
<title>Integrated Stress Response Potentiates Ponatinib-Induced Cardiotoxicity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38323474/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240207211355&amp;v=2.18.0
      <description>CONCLUSIONS: Neutralizing ISR hyperactivation could prevent or reverse ponatinib-induced cardiotoxicity. The findings that compromised ATP production potentiates GCN2-mediated ISR activation have broad implications across various cardiac diseases. Our results also highlight an unanticipated role of ponatinib in causing direct activation of a kinase target despite its role as an ATP-competitive kinase inhibitor.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Feb 7. doi: 10.1161/CIRCRESAHA.123.323683. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Mitochondrial dysfunction is a primary driver of cardiac contractile failure; yet, the cross talk between mitochondrial energetics and signaling regulation remains obscure. Ponatinib, a tyrosine kinase inhibitor used to treat chronic myeloid leukemia, is among the most cardiotoxic tyrosine kinase inhibitors and causes mitochondrial dysfunction. Whether ponatinib-induced mitochondrial dysfunction triggers the integrated stress response (ISR) to induce ponatinib-induced cardiotoxicity remains to be determined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using human-induced pluripotent stem cells-derived cardiomyocytes (hiPSC-CMs) and a recently developed mouse model of ponatinib-induced cardiotoxicity, we performed proteomic analysis, molecular and biochemical assays to investigate the relationship between ponatinib-induced mitochondrial stress and ISR and their role in promoting ponatinib-induced cardiotoxicity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Proteomic analysis revealed that ponatinib activated the ISR in cardiac cells. We identified GCN2 (general control nonderepressible 2) as the eIF2α (eukaryotic translation initiation factor) kinase responsible for relaying mitochondrial stress signals to trigger the primary ISR effector-ATF4 (activating transcription factor 4), upon ponatinib exposure. Mechanistically, ponatinib treatment exerted inhibitory effects on ATP synthase activity and reduced its expression levels resulting in ATP deficits. Perturbed mitochondrial function resulting in ATP deficits then acts as a trigger of GCN2-mediated ISR activation, effects that were negated by nicotinamide mononucleotide, an NAD<sup>+</sup> precursor, supplementation. Genetic inhibition of ATP synthase also activated GCN2. Interestingly, we showed that the decreased abundance of ATP also facilitated direct binding of ponatinib to GCN2, unexpectedly causing its activation most likely because of a conformational change in its structure. Importantly, administering an ISR inhibition, ISRIB, protected human-induced pluripotent stem cell-derived cardiomyocytes against ponatinib. Ponatinib-treated mice also exhibited reduced cardiac function, effects that were attenuated upon systemic ISRIB administration. Importantly, ISRIB does not affect the antitumor effects of ponatinib in vitro.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Neutralizing ISR hyperactivation could prevent or reverse ponatinib-induced cardiotoxicity. The findings that compromised ATP production potentiates GCN2-mediated ISR activation have broad implications across various cardiac diseases. Our results also highlight an unanticipated role of ponatinib in causing direct activation of a kinase target despite its role as an ATP-competitive kinase inhibitor.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38323474/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240207211355&v=2.18.0">38323474</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323683>10.1161/CIRCRESAHA.123.323683</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38323474</guid>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Gege Yan</dc:creator>
<dc:creator>Zhenbo Han</dc:creator>
<dc:creator>Youjeong Kwon</dc:creator>
<dc:creator>Jordan Jousma</dc:creator>
<dc:creator>Sarath Babu Nukala</dc:creator>
<dc:creator>Benjamin L Prosser</dc:creator>
<dc:creator>Xiaoping Du</dc:creator>
<dc:creator>Sandra Pinho</dc:creator>
<dc:creator>Sang-Bing Ong</dc:creator>
<dc:creator>Won Hee Lee</dc:creator>
<dc:creator>Sang-Ging Ong</dc:creator>
<dc:date>2024-02-07</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Integrated Stress Response Potentiates Ponatinib-Induced Cardiotoxicity</dc:title>
<dc:identifier>pmid:38323474</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323683</dc:identifier>
</item>
<item>
<title>Exercise Inhibits Doxorubicin-Induced Cardiotoxicity via Regulating B Cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38323433/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240207211355&amp;v=2.18.0
      <description>CONCLUSIONS: Our results demonstrate that exercise training protects against Dox-induced cardiotoxicity by upregulating Fc gamma receptor IIB expression in B cells, which plays an important anti-inflammatory role and participates in the protective effect of exercise against Dox-induced cardiotoxicity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Feb 7. doi: 10.1161/CIRCRESAHA.123.323346. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Doxorubicin (Dox) is an effective chemotherapeutic agent, but its use is limited by acute and chronic cardiotoxicity. Exercise training has been shown to protect against Dox-induced cardiotoxicity, but the involvement of immune cells remains unclear. This study aimed to investigate the role of exercise-derived B cells in protecting against Dox-induced cardiotoxicity and to further determine whether B cell activation and antibody secretion play a role in this protection.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Mice that were administered with Dox (5 mg/kg per week, 20 mg/kg cumulative dose) received treadmill running exercise. The adoptive transfer of exercise-derived splenic B cells to μMT<sup>-/-</sup> (B cell-deficient) mice was performed to elucidate the mechanism of B cell regulation that mediated the effect of exercise.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Dox-administered mice that had undergone exercise training showed improved cardiac function, and low levels of cardiac apoptosis, atrophy, and fibrosis, and had reduced cardiac antibody deposition and proinflammatory responses. Similarly, B cell pharmacological and genetic depletion alleviated Dox-induced cardiotoxicity, which phenocopied the protection of exercise. In vitro performed coculture experiments confirmed that exercise-derived B cells reduced cardiomyocyte apoptosis and fibroblast activation compared with control B cells. Importantly, the protective effect of exercise on B cells was confirmed by the adoptive transfer of splenic B cells from exercised donor mice to μMT<sup>-/-</sup> recipient mice. However, blockage of Fc gamma receptor IIB function using B cell transplants from exercised Fc gamma receptor IIB<sup>-/-</sup> mice abolished the protection of exercise-derived B cells against Dox-induced cardiotoxicity. Mechanistically, we found that Fc gamma receptor IIB, an important B cell inhibitory receptor, responded to exercise and increased B cell activation threshold, which participated in exercise-induced protection against Dox-induced cardiotoxicity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our results demonstrate that exercise training protects against Dox-induced cardiotoxicity by upregulating Fc gamma receptor IIB expression in B cells, which plays an important anti-inflammatory role and participates in the protective effect of exercise against Dox-induced cardiotoxicity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38323433/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240207211355&v=2.18.0">38323433</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323346>10.1161/CIRCRESAHA.123.323346</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38323433</guid>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Jing Wang</dc:creator>
<dc:creator>Shuqin Liu</dc:creator>
<dc:creator>Xinxiu Meng</dc:creator>
<dc:creator>Xuan Zhao</dc:creator>
<dc:creator>Tianhui Wang</dc:creator>
<dc:creator>Zhiyong Lei</dc:creator>
<dc:creator>H Immo Lehmann</dc:creator>
<dc:creator>Guoping Li</dc:creator>
<dc:creator>Pilar Alcaide</dc:creator>
<dc:creator>Yihua Bei</dc:creator>
<dc:creator>Junjie Xiao</dc:creator>
<dc:date>2024-02-07</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Exercise Inhibits Doxorubicin-Induced Cardiotoxicity via Regulating B Cells</dc:title>
<dc:identifier>pmid:38323433</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323346</dc:identifier>
</item>
<item>
<title>Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38321820/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240207211355&amp;v=2.18.0
      <description>CONCLUSIONS: In patients with severe AS and lower surgical risk randomized to TAVI or SAVR, the risk of major clinical outcomes was not different 10 years after treatment. The risk of severe bioprosthesis SVD was lower after TAVR compared with SAVR, while the risk of BVF was similar.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 7:ehae043. doi: 10.1093/eurheartj/ehae043. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Transcatheter aortic valve implantation (TAVI) has become a viable treatment option for patients with severe aortic valve stenosis across a broad range of surgical risk. The Nordic Aortic Valve Intervention (NOTION) trial was the first to randomize patients at lower surgical risk to TAVI or surgical aortic valve replacement (SAVR). The aim of the present study was to report clinical and bioprosthesis outcomes after 10 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The NOTION trial randomized 280 patients to TAVI with the self-expanding CoreValve (Medtronic Inc.) bioprosthesis (n = 145) or SAVR with a bioprosthesis (n = 135). The primary composite outcome was the risk of all-cause mortality, stroke, or myocardial infarction. Bioprosthetic valve dysfunction (BVD) was classified as structural valve deterioration (SVD), non-structural valve dysfunction (NSVD), clinical valve thrombosis, or endocarditis according to Valve Academic Research Consortium-3 criteria. Severe SVD was defined as (i) a transprosthetic gradient of 30 mmHg or more and an increase in transprosthetic gradient of 20 mmHg or more or (ii) severe new intraprosthetic regurgitation. Bioprosthetic valve failure (BVF) was defined as the composite rate of death from a valve-related cause or an unexplained death following the diagnosis of BVD, aortic valve re-intervention, or severe SVD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Baseline characteristics were similar between TAVI and SAVR: age 79.2 ± 4.9 years and 79.0 ± 4.7 years (P = .7), male 52.6% and 53.8% (P = .8), and Society of Thoracic Surgeons score &lt; 4% of 83.4% and 80.0% (P = .5), respectively. After 10 years, the risk of the composite outcome all-cause mortality, stroke, or myocardial infarction was 65.5% after TAVI and 65.5% after SAVR [hazard ratio (HR) 1.0; 95% confidence interval (CI) 0.7-1.3; P = .9], with no difference for each individual outcome. Severe SVD had occurred in 1.5% and 10.0% (HR 0.2; 95% CI 0.04-0.7; P = .02) after TAVI and SAVR, respectively. The cumulative incidence for severe NSVD was 20.5% and 43.0% (P &lt; .001) and for endocarditis 7.2% and 7.4% (P = 1.0) after TAVI and SAVR, respectively. No patients had clinical valve thrombosis. Bioprosthetic valve failure occurred in 9.7% of TAVI and 13.8% of SAVR patients (HR 0.7; 95% CI 0.4-1.5; P = .4).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with severe AS and lower surgical risk randomized to TAVI or SAVR, the risk of major clinical outcomes was not different 10 years after treatment. The risk of severe bioprosthesis SVD was lower after TAVR compared with SAVR, while the risk of BVF was similar.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38321820/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240207211355&v=2.18.0">38321820</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae043>10.1093/eurheartj/ehae043</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38321820</guid>
<pubDate>Wed, 07 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Hans Gustav Hørsted Thyregod</dc:creator>
<dc:creator>Troels Højsgaard Jørgensen</dc:creator>
<dc:creator>Nikolaj Ihlemann</dc:creator>
<dc:creator>Daniel Andreas Steinbrüchel</dc:creator>
<dc:creator>Henrik Nissen</dc:creator>
<dc:creator>Bo Juel Kjeldsen</dc:creator>
<dc:creator>Petur Petursson</dc:creator>
<dc:creator>Ole De Backer</dc:creator>
<dc:creator>Peter Skov Olsen</dc:creator>
<dc:creator>Lars Søndergaard</dc:creator>
<dc:date>2024-02-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial</dc:title>
<dc:identifier>pmid:38321820</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae043</dc:identifier>
</item>
<item>
<title>Human papilloma virus and atherosclerotic cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38321363/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240207211355&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 7:ehad829. doi: 10.1093/eurheartj/ehad829. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38321363/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240207211355&v=2.18.0">38321363</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad829>10.1093/eurheartj/ehad829</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38321363</guid>
<pubDate>Tue, 06 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Noel C Chan</dc:creator>
<dc:creator>James S Lawson</dc:creator>
<dc:creator>Jack Hirsh</dc:creator>
<dc:date>2024-02-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Human papilloma virus and atherosclerotic cardiovascular disease</dc:title>
<dc:identifier>pmid:38321363</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad829</dc:identifier>
</item>
<item>
<title>Human papillomavirus infection and cardiovascular mortality: a cohort study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38321359/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240207211355&amp;v=2.18.0
      <description>CONCLUSIONS: In this cohort study of young and middle-aged Korean women, at low risks for CVD mortality, those with HR-HPV infection had higher death rates from CVD, specifically ASCVD and IHD, with a more pronounced trend in obese individuals.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 7:ehae020. doi: 10.1093/eurheartj/ehae020. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: High-risk human papillomavirus (HR-HPV) infection-a well-established risk factor for cervical cancer-has associations with cardiovascular disease (CVD). However, its relationship with CVD mortality remains uncertain. This study examined the associations between HR-HPV infection and CVD mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: As part of a health examination, 163 250 CVD-free Korean women (mean age: 40.2 years) underwent HR-HPV screening and were tracked for up to 17 years (median: 8.6 years). National death records identified the CVD mortality cases. Hazard ratios (HRs) and 95% confidence intervals (CIs) for CVD mortality were estimated using Cox proportional hazard regression analyses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During 1 380 953 person-years of follow-up, 134 CVD deaths occurred, with a mortality rate of 9.1 per 105 person-years for HR-HPV(-) women and 14.9 per 105 person-years for HR-HPV(+) women. After adjustment for traditional CVD risk factors and confounders, the HRs (95% CI) for atherosclerotic CVD (ASCVD), ischaemic heart disease (IHD), and stroke mortality in women with HR-HPV infection compared with those without infection were 3.91 (1.85-8.26), 3.74 (1.53-9.14), and 5.86 (0.86-40.11), respectively. The association between HR-HPV infection and ASCVD mortality was stronger in women with obesity than in those without (P for interaction = .006), with corresponding HRs (95% CI) of 4.81 (1.55-14.93) for obese women and 2.86 (1.04-7.88) for non-obese women.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this cohort study of young and middle-aged Korean women, at low risks for CVD mortality, those with HR-HPV infection had higher death rates from CVD, specifically ASCVD and IHD, with a more pronounced trend in obese individuals.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38321359/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240207211355&v=2.18.0">38321359</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae020>10.1093/eurheartj/ehae020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38321359</guid>
<pubDate>Tue, 06 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Hae Suk Cheong</dc:creator>
<dc:creator>Yoosoo Chang</dc:creator>
<dc:creator>Yejin Kim</dc:creator>
<dc:creator>Min-Jung Kwon</dc:creator>
<dc:creator>Yoosun Cho</dc:creator>
<dc:creator>Bomi Kim</dc:creator>
<dc:creator>Eun-Jeong Joo</dc:creator>
<dc:creator>Young Ho Bae</dc:creator>
<dc:creator>Chanmin Kim</dc:creator>
<dc:creator>Seungho Ryu</dc:creator>
<dc:date>2024-02-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Human papillomavirus infection and cardiovascular mortality: a cohort study</dc:title>
<dc:identifier>pmid:38321359</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae020</dc:identifier>
</item>
<item>
<title>PARP1-DNA co-condensation drives DNA repair site assembly to prevent disjunction of broken DNA ends</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38320550/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240207211355&amp;v=2.18.0
      <description>DNA double-strand breaks (DSBs) are repaired at DSB sites. How DSB sites assemble and how broken DNA is prevented from separating is not understood. Here we uncover that the synapsis of broken DNA is mediated by the DSB sensor protein poly(ADP-ribose) (PAR) polymerase 1 (PARP1). Using bottom-up biochemistry, we reconstitute functional DSB sites and show that DSB sites form through co-condensation of PARP1 multimers with DNA. The co-condensates exert mechanical forces to keep DNA ends together...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jan 31:S0092-8674(24)00052-7. doi: 10.1016/j.cell.2024.01.015. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DNA double-strand breaks (DSBs) are repaired at DSB sites. How DSB sites assemble and how broken DNA is prevented from separating is not understood. Here we uncover that the synapsis of broken DNA is mediated by the DSB sensor protein poly(ADP-ribose) (PAR) polymerase 1 (PARP1). Using bottom-up biochemistry, we reconstitute functional DSB sites and show that DSB sites form through co-condensation of PARP1 multimers with DNA. The co-condensates exert mechanical forces to keep DNA ends together and become enzymatically active for PAR synthesis. PARylation promotes release of PARP1 from DNA ends and the recruitment of effectors, such as Fused in Sarcoma, which stabilizes broken DNA ends against separation, revealing a finely orchestrated order of events that primes broken DNA for repair. We provide a comprehensive model for the hierarchical assembly of DSB condensates to explain DNA end synapsis and the recruitment of effector proteins for DNA damage repair.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38320550/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240207211355&v=2.18.0">38320550</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.01.015>10.1016/j.cell.2024.01.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38320550</guid>
<pubDate>Tue, 06 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Nagaraja Chappidi</dc:creator>
<dc:creator>Thomas Quail</dc:creator>
<dc:creator>Simon Doll</dc:creator>
<dc:creator>Laura T Vogel</dc:creator>
<dc:creator>Radoslav Aleksandrov</dc:creator>
<dc:creator>Suren Felekyan</dc:creator>
<dc:creator>Ralf Kühnemuth</dc:creator>
<dc:creator>Stoyno Stoynov</dc:creator>
<dc:creator>Claus A M Seidel</dc:creator>
<dc:creator>Jan Brugués</dc:creator>
<dc:creator>Marcus Jahnel</dc:creator>
<dc:creator>Titus M Franzmann</dc:creator>
<dc:creator>Simon Alberti</dc:creator>
<dc:date>2024-02-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>PARP1-DNA co-condensation drives DNA repair site assembly to prevent disjunction of broken DNA ends</dc:title>
<dc:identifier>pmid:38320550</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.01.015</dc:identifier>
</item>
<item>
<title>A synthetic differentiation circuit in Escherichia coli for suppressing mutant takeover</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38320549/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240207211355&amp;v=2.18.0
      <description>Differentiation is crucial for multicellularity. However, it is inherently susceptible to mutant cells that fail to differentiate. These mutants outcompete normal cells by excessive self-renewal. It remains unclear what mechanisms can resist such mutant expansion. Here, we demonstrate a solution by engineering a synthetic differentiation circuit in Escherichia coli that selects against these mutants via a biphasic fitness strategy. The circuit provides tunable production of synthetic analogs of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jan 31:S0092-8674(24)00061-8. doi: 10.1016/j.cell.2024.01.024. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Differentiation is crucial for multicellularity. However, it is inherently susceptible to mutant cells that fail to differentiate. These mutants outcompete normal cells by excessive self-renewal. It remains unclear what mechanisms can resist such mutant expansion. Here, we demonstrate a solution by engineering a synthetic differentiation circuit in Escherichia coli that selects against these mutants via a biphasic fitness strategy. The circuit provides tunable production of synthetic analogs of stem, progenitor, and differentiated cells. It resists mutations by coupling differentiation to the production of an essential enzyme, thereby disadvantaging non-differentiating mutants. The circuit selected for and maintained a positive differentiation rate in long-term evolution. Surprisingly, this rate remained constant across vast changes in growth conditions. We found that transit-amplifying cells (fast-growing progenitors) underlie this environmental robustness. Our results provide insight into the stability of differentiation and demonstrate a powerful method for engineering evolutionarily stable multicellular consortia.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38320549/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240207211355&v=2.18.0">38320549</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.01.024>10.1016/j.cell.2024.01.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38320549</guid>
<pubDate>Tue, 06 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>David S Glass</dc:creator>
<dc:creator>Anat Bren</dc:creator>
<dc:creator>Elizabeth Vaisbourd</dc:creator>
<dc:creator>Avi Mayo</dc:creator>
<dc:creator>Uri Alon</dc:creator>
<dc:date>2024-02-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A synthetic differentiation circuit in Escherichia coli for suppressing mutant takeover</dc:title>
<dc:identifier>pmid:38320549</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.01.024</dc:identifier>
</item>
<item>
<title>Lipoprotein(a) association with residual risk: what has inflammation got to do with it?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38320259/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240207211355&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 6:ehae045. doi: 10.1093/eurheartj/ehae045. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38320259/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240207211355&v=2.18.0">38320259</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae045>10.1093/eurheartj/ehae045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38320259</guid>
<pubDate>Tue, 06 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Zareen M Farukhi</dc:creator>
<dc:creator>Samia Mora</dc:creator>
<dc:date>2024-02-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Lipoprotein(a) association with residual risk: what has inflammation got to do with it?</dc:title>
<dc:identifier>pmid:38320259</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae045</dc:identifier>
</item>
<item>
<title>Multimodality imaging of acute intramyocardial dissecting haematoma and its dynamic progression</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38320253/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240207211355&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 6:ehae035. doi: 10.1093/eurheartj/ehae035. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38320253/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240207211355&v=2.18.0">38320253</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae035>10.1093/eurheartj/ehae035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38320253</guid>
<pubDate>Tue, 06 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Wan-Yu Hu</dc:creator>
<dc:creator>Bo-Wen Zhao</dc:creator>
<dc:creator>Chen-Yang Jiang</dc:creator>
<dc:date>2024-02-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Multimodality imaging of acute intramyocardial dissecting haematoma and its dynamic progression</dc:title>
<dc:identifier>pmid:38320253</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae035</dc:identifier>
</item>
<item>
<title>Scoring systems developed by machine learning: intelligent but simple to use?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38320252/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240207211355&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 6:ehae053. doi: 10.1093/eurheartj/ehae053. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38320252/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240207211355&v=2.18.0">38320252</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae053>10.1093/eurheartj/ehae053</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38320252</guid>
<pubDate>Tue, 06 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Abhirup Banerjee</dc:creator>
<dc:creator>Paul Leeson</dc:creator>
<dc:date>2024-02-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Scoring systems developed by machine learning: intelligent but simple to use?</dc:title>
<dc:identifier>pmid:38320252</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae053</dc:identifier>
</item>
<item>
<title>A paradigm change in sudden cardiac death risk prediction: 'static' goes out, 'dynamic' comes in</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38320251/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240207211355&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 6:ehae051. doi: 10.1093/eurheartj/ehae051. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38320251/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240207211355&v=2.18.0">38320251</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae051>10.1093/eurheartj/ehae051</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38320251</guid>
<pubDate>Tue, 06 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Peter J Schwartz</dc:creator>
<dc:creator>Paolo Cerea</dc:creator>
<dc:date>2024-02-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A paradigm change in sudden cardiac death risk prediction: 'static' goes out, 'dynamic' comes in</dc:title>
<dc:identifier>pmid:38320251</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae051</dc:identifier>
</item>
<item>
<title>Clonal haematopoiesis and cardiac arrythmias: rhythm-altering mutations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38320247/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240207211355&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 6:ehae052. doi: 10.1093/eurheartj/ehae052. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38320247/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240207211355&v=2.18.0">38320247</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae052>10.1093/eurheartj/ehae052</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38320247</guid>
<pubDate>Tue, 06 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>María A Zuriaga</dc:creator>
<dc:creator>Domingo Pascual-Figal</dc:creator>
<dc:creator>José J Fuster</dc:creator>
<dc:date>2024-02-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Clonal haematopoiesis and cardiac arrythmias: rhythm-altering mutations</dc:title>
<dc:identifier>pmid:38320247</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae052</dc:identifier>
</item>
<item>
<title>Lowering dietary sodium intake to reduce blood pressure: cum grano salis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38320239/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240207211355&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 6:ehae065. doi: 10.1093/eurheartj/ehae065. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38320239/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240207211355&v=2.18.0">38320239</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae065>10.1093/eurheartj/ehae065</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38320239</guid>
<pubDate>Tue, 06 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2024-02-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Lowering dietary sodium intake to reduce blood pressure: cum grano salis</dc:title>
<dc:identifier>pmid:38320239</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae065</dc:identifier>
</item>
<item>
<title>Mineralocorticoid receptor antagonists for the prevention of atrial fibrillation in patients with and without heart failure: one more beneficial effect?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38319069/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240207211355&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 6:ehae040. doi: 10.1093/eurheartj/ehae040. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38319069/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240207211355&v=2.18.0">38319069</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae040>10.1093/eurheartj/ehae040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38319069</guid>
<pubDate>Tue, 06 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Daniela Zurkan</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Frank Edelmann</dc:creator>
<dc:date>2024-02-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Mineralocorticoid receptor antagonists for the prevention of atrial fibrillation in patients with and without heart failure: one more beneficial effect?</dc:title>
<dc:identifier>pmid:38319069</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae040</dc:identifier>
</item>
<item>
<title>Less Obvious Than One Might Think: Why Is There Grouped Beating?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38315765/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240207211355&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 6;149(6):481-483. doi: 10.1161/CIRCULATIONAHA.123.068252. Epub 2024 Feb 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38315765/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240207211355&v=2.18.0">38315765</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068252>10.1161/CIRCULATIONAHA.123.068252</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38315765</guid>
<pubDate>Mon, 05 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Adrian M Petzl</dc:creator>
<dc:creator>Andrew E Epstein</dc:creator>
<dc:creator>Gustavo S Guandalini</dc:creator>
<dc:date>2024-02-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Less Obvious Than One Might Think: Why Is There Grouped Beating?</dc:title>
<dc:identifier>pmid:38315765</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068252</dc:identifier>
</item>
<item>
<title>Giants Hiding in Small Places: A Case of New Onset Heart Failure, Atrioventricular Block, and Ventricular Arrhythmias</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38315764/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240207211355&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 6;149(6):475-480. doi: 10.1161/CIRCULATIONAHA.123.066747. Epub 2024 Feb 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38315764/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240207211355&v=2.18.0">38315764</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC10846671/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240207211355&v=2.18.0">PMC10846671</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066747>10.1161/CIRCULATIONAHA.123.066747</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38315764</guid>
<pubDate>Mon, 05 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Reynaldo H Sanchez</dc:creator>
<dc:creator>Hanan Hamdan</dc:creator>
<dc:creator>Jose Torrealba</dc:creator>
<dc:creator>Justin L Grodin</dc:creator>
<dc:date>2024-02-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Giants Hiding in Small Places: A Case of New Onset Heart Failure, Atrioventricular Block, and Ventricular Arrhythmias</dc:title>
<dc:identifier>pmid:38315764</dc:identifier>
<dc:identifier>pmc:PMC10846671</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066747</dc:identifier>
</item>
<item>
<title>The Electrocardiogram at 100 Years: History and Future</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38315763/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240207211355&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 6;149(6):411-413. doi: 10.1161/CIRCULATIONAHA.123.065489. Epub 2024 Feb 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38315763/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240207211355&v=2.18.0">38315763</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065489>10.1161/CIRCULATIONAHA.123.065489</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38315763</guid>
<pubDate>Mon, 05 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Paul A Friedman</dc:creator>
<dc:date>2024-02-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Electrocardiogram at 100 Years: History and Future</dc:title>
<dc:identifier>pmid:38315763</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065489</dc:identifier>
</item>





























</channel>
</rss>